Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Amx0035 conditional approval in Canada
View:
Post by M101 on Jun 13, 2022 4:22pm

Amx0035 conditional approval in Canada

Wonder if this has Cashman thinking about pmn267 approval strategy? 

https://endpts.com/amylyx-picks-up-als-drug-approval-in-canada-after-fda-asks-for-more-time-to-review-the-data/
Comment by Speyeder999 on Jun 13, 2022 7:33pm
Hopefully Rudy Tanzi can bring some of this positive momentum our way seeing he is also SAB chair for Promis.
Comment by FarmerBetty on Jun 14, 2022 12:43am
Rudy Tanzi has been on Promis for a number of years, seeing very liittle new talked about before just because he is chair. Haven't heard any more about the google project no surprize. There time has finally come with there AD, ALS, PD  products look back how they have streched.
ProMIS Neurosciences Inc